Serotonin transporter (SERT) gene polymorphism in Parkinson’s disease

Background: Parkinson disease (PD) is the second most common neurodegenerative disorder with a prevalence of about 2% in persons older than 65 years of age. Neurodegenerative process in PD is not restricted to the dopaminergic neurons of the substantia nigra but also affects serotoninergic neuro...

Full description

Bibliographic Details
Main Authors: Mahmut Özkaya, Okan Do¤u, Serhan Sevim, Handan Çamdeviren, Deniz Yalç›nkaya, Mehmet Emin Erdal
Format: Article
Language:English
Published: Galenos Yayinevi 2004-06-01
Series:Türk Nöroloji Dergisi
Subjects:
Online Access:https://www.journalagent.com/tjn/pdfs/TJN_10_3_201_205.pdf
id doaj-0b18e544f6a247bea3da534fd4dcb0b9
record_format Article
spelling doaj-0b18e544f6a247bea3da534fd4dcb0b92021-09-02T15:19:42ZengGalenos YayineviTürk Nöroloji Dergisi1301-062X1309-25452004-06-01103201205Serotonin transporter (SERT) gene polymorphism in Parkinson’s diseaseMahmut Özkaya0Okan Do¤u1Serhan Sevim2Handan Çamdeviren3Deniz Yalç›nkaya4Mehmet Emin Erdal5Mersin Üniversitesi T›p Fakültesi T›bbi Biyoloji ve GenetikMersin Üniversitesi T›p Fakültesi Nöroloj Anabilim Dal›Mersin Üniversitesi T›p Fakültesi Nöroloj Anabilim Dal›Mersin Üniversitesi T›p Fakültesi Biyoistatistik Anabilim Dal›Mersin Üniversitesi T›p Fakültesi Nöroloj Anabilim Dal›Mersin Üniversitesi T›p Fakültesi T›bbi Biyoloji ve GenetikBackground: Parkinson disease (PD) is the second most common neurodegenerative disorder with a prevalence of about 2% in persons older than 65 years of age. Neurodegenerative process in PD is not restricted to the dopaminergic neurons of the substantia nigra but also affects serotoninergic neurons. It has been shown that PD brains with Lewy bodies in the substantia nigra also had Lewy bodies in the raphe nuclei. The re-uptake of 5HT released into the synaptic cleft is mediated by the 5HT transporter (SERT). The SERT gene has been mapped to the chromosome of 17q11.1-q12 and has two main polymorphisms: intron two VNTR polymorphism and promoter region 44 bp insertion/deletion polymorphism. Objective: In this study we investigated whether two polymorphic regions in the serotonin transporter gene are associated with PD. Material and Method: After obtaining informed consent, blood samples were collected from 76 patients and 54 healthy volunteers. Genomic DNA was extracted from peripheral leucocytes using standard methods. The SERT gene genotypes were determined using polymerase chain reaction (PCR) method. Results: Based on the intron 2 VNTR polymorphism of SERT gene, the distribution of 12/12, 12/10 and 10/10 genotypes were found as, 56.6 %, 35.5 %, 7.9 % in patients whereas this genotype distribution in control group was 40.7 %, 46.3 % and 13 %, respectively. According to 5-HTTLPR polymorphism, the distribution of L/L, L/S and S/S genotypes were found as 27.6 % 51.3 % and 21.1 % in patients whereas this genotype distribution in control group was 33.4 %, 50.0 % and 16.6 %, respectively. Despite the fact that the genotype distribution of SERT gene polymorphism in patients and control group seemed to be different from each other, this difference was not found to be statistically significant. Conclusion: This finding suggests that polymorphisms within the SERT gene do not play a major role in PD susceptibility in the Turkish population.https://www.journalagent.com/tjn/pdfs/TJN_10_3_201_205.pdfserotonin transporter (SERT) geneParkinson’s diseasegenetic polymorphism
collection DOAJ
language English
format Article
sources DOAJ
author Mahmut Özkaya
Okan Do¤u
Serhan Sevim
Handan Çamdeviren
Deniz Yalç›nkaya
Mehmet Emin Erdal
spellingShingle Mahmut Özkaya
Okan Do¤u
Serhan Sevim
Handan Çamdeviren
Deniz Yalç›nkaya
Mehmet Emin Erdal
Serotonin transporter (SERT) gene polymorphism in Parkinson’s disease
Türk Nöroloji Dergisi
serotonin transporter (SERT) gene
Parkinson’s disease
genetic polymorphism
author_facet Mahmut Özkaya
Okan Do¤u
Serhan Sevim
Handan Çamdeviren
Deniz Yalç›nkaya
Mehmet Emin Erdal
author_sort Mahmut Özkaya
title Serotonin transporter (SERT) gene polymorphism in Parkinson’s disease
title_short Serotonin transporter (SERT) gene polymorphism in Parkinson’s disease
title_full Serotonin transporter (SERT) gene polymorphism in Parkinson’s disease
title_fullStr Serotonin transporter (SERT) gene polymorphism in Parkinson’s disease
title_full_unstemmed Serotonin transporter (SERT) gene polymorphism in Parkinson’s disease
title_sort serotonin transporter (sert) gene polymorphism in parkinson’s disease
publisher Galenos Yayinevi
series Türk Nöroloji Dergisi
issn 1301-062X
1309-2545
publishDate 2004-06-01
description Background: Parkinson disease (PD) is the second most common neurodegenerative disorder with a prevalence of about 2% in persons older than 65 years of age. Neurodegenerative process in PD is not restricted to the dopaminergic neurons of the substantia nigra but also affects serotoninergic neurons. It has been shown that PD brains with Lewy bodies in the substantia nigra also had Lewy bodies in the raphe nuclei. The re-uptake of 5HT released into the synaptic cleft is mediated by the 5HT transporter (SERT). The SERT gene has been mapped to the chromosome of 17q11.1-q12 and has two main polymorphisms: intron two VNTR polymorphism and promoter region 44 bp insertion/deletion polymorphism. Objective: In this study we investigated whether two polymorphic regions in the serotonin transporter gene are associated with PD. Material and Method: After obtaining informed consent, blood samples were collected from 76 patients and 54 healthy volunteers. Genomic DNA was extracted from peripheral leucocytes using standard methods. The SERT gene genotypes were determined using polymerase chain reaction (PCR) method. Results: Based on the intron 2 VNTR polymorphism of SERT gene, the distribution of 12/12, 12/10 and 10/10 genotypes were found as, 56.6 %, 35.5 %, 7.9 % in patients whereas this genotype distribution in control group was 40.7 %, 46.3 % and 13 %, respectively. According to 5-HTTLPR polymorphism, the distribution of L/L, L/S and S/S genotypes were found as 27.6 % 51.3 % and 21.1 % in patients whereas this genotype distribution in control group was 33.4 %, 50.0 % and 16.6 %, respectively. Despite the fact that the genotype distribution of SERT gene polymorphism in patients and control group seemed to be different from each other, this difference was not found to be statistically significant. Conclusion: This finding suggests that polymorphisms within the SERT gene do not play a major role in PD susceptibility in the Turkish population.
topic serotonin transporter (SERT) gene
Parkinson’s disease
genetic polymorphism
url https://www.journalagent.com/tjn/pdfs/TJN_10_3_201_205.pdf
work_keys_str_mv AT mahmutozkaya serotonintransportersertgenepolymorphisminparkinsonsdisease
AT okandou serotonintransportersertgenepolymorphisminparkinsonsdisease
AT serhansevim serotonintransportersertgenepolymorphisminparkinsonsdisease
AT handancamdeviren serotonintransportersertgenepolymorphisminparkinsonsdisease
AT denizyalcnkaya serotonintransportersertgenepolymorphisminparkinsonsdisease
AT mehmeteminerdal serotonintransportersertgenepolymorphisminparkinsonsdisease
_version_ 1721173861234376704